Prevalence of bla_{CTX M} Extended Spectrum Beta Lactamase Gene in Enterobacteriaceae from Critical Care Patients

INTRODUCTION

Antimicrobial resistance is an emerging problem in treating the critically ill patients. The production of extended-spectrum beta-lactamase (ESBL) is one of the most important mechanisms of antimicrobial resistance. Recent increase in number of ESBLs attributes to the emergence of beta-lactamase producing bla _{CTX M} gene in Enterobacteriaceae. ^[1] This study focuses on detecting bla _{CTX M} ESBL producing Enterobacteriaceae from infections in critical care patients and to bring awareness to the clinicians about the intensity of the problem and to make interventions to curb the emergence and dissemination of CTX M ESBLs.

MATERIALS AND METHODS

A total of 118 Enterobacteriaceae from critical care units patients were recovered over a period of eight months (January 2010 to August 2010) from a variety of clinical specimens, i.e. urine, pus, sputum, blood, catheter tips, tracheal secretions, endotracheal tube etc. Identification of these isolates was done based on colony morphology on blood agar, MacConkey agar and by standard biochemical reactions. ^[2] Antibiotic susceptibility testing was done on Muller-Hinton agar after standardizing the suspension to 0.5 McFarland's standards. The sensitivity of the isolates to 3 GC (Ceftriaxone, Ceftazidime and Cefotaxime) and to the other antibiotics such as Cotrimoxazole, Amikacin, Ciprofloxacin, Cefepime (Fourth generation cephalosporins), Augumentin and Imepenem was determined by Disc Diffusion Method. The results were interpreted as per Clinical and Laboratory Standards Institute (CLSI) recommendations. ^[3] Escherichia coli ATCC 25922 strain was used for quality control. Isolates with resistance or with reduced Susceptibility to Ceftriaxone (‹ 21 mm), Ceftazidime (‹ 18 mm) and Cefotaxime (‹ 20 mm) were selected for the study.

RESULTS

A total of 118 Enterobacteriaceae isolates were obtained during the study period, of which 68 isolates showed enhanced zone size towards the Augmentin disc and were considered positive for ESBL by DDST. Of the 68 isolates, the zone around Cefatoxime was enhanced towards Augmentin in 51 isolates. Multiplex PCR yielded the products with predicted size for group 1 CTX-M (499 bp) enzyme in 54 isolates. The distribution of organisms in Enterobacteriaceae, results of their phenotypic confirmation for ESBL and PCR for CTX M were given in Table 1. MIC of 3GC antibiotics for ESBL producing Enterobacteriaceae is shown in Table 2. In our study among the 118 isolates of Enterobacteriaceae, 54 isolates were positive for CTX-M extended spectrum beta lactamase which constitutes 45.7% [Table 3] None of the isolates were Positive for CTX-M group II, CTX-M group III and CTX-M group IV ESBL's.

DISCUSSION

Many patients have to be hospitalized for a long duration and treated with heavy dose of antibiotics in the Critical Care units which facilitate them to acquire infection with multi drug resistant organisms. ^[7-9] Furthermore, there is a remarkable rise in morbidity and mortality as well as the expenses for the patients in the critical care units. ^[10,11] The commonest way of acquiring antibiotic resistance is by inactivating the antibiotic by the production of enzymes like beta-lactamases. The production of ESBLs is one of the most important mechanisms of antimicrobial resistance. Recent increase in number of ESBLs attributes to the emergence of CTX-M beta-lactamase producing Enterobacteriaceae. ^[1] Many studies have been conducted in the Critical Care units regarding antimicrobial resistant organisms. ^[11-14] But very few studies have been conducted about CTX M beta lactamases as bla_CTXM is newly emerged gene of ESBL having preference for Enterobacteriaceae. ^[15,16] In our study, 68 isolates were found to be ESBL producers by phenotypic confirmation. Among them 35 isolates were Escherichia coli, 27 isolates were Klebsiella species. and 6 isolates were Proteus species. Among the 68 ESBL producers, 54 isolates were positive for CTX-M group I ESBL and all the isolates were negative for other CTX M Groups (Group II, III and IV) confirmed by PCR. These data could indicate that the ESBL phenotype is due to production of ESBLs other than CTX-Ms. This also shows that CTX-M group I is the predominant form in Enterobacteriaceae. ^[17] Our study is in accordance with James. S, et al. in which the most common CTX-M-type ESBL was CTX-M-15 in the critically ill patients recovered from blood and other sterile fluids. ^[18] Macrorestriction polymorphism of genomic is DNA determined by Pulse Field Gel Electrophoresis would indicate whether CTX M - 15 producing Enterobacteriaceae strains belong to a single clone. ^[19] The major clones of Escherichia coli isolates with CTX M - 15 Beta lactamase had 78% similarity by PFGE and may share a common ancestor as stated by D.M. Livermore, P.M. Howkey, et al. CTX-M group I includes CTX- M-1, M-3, M-10 to M-12, M-15, M-22, M-23, M-28, M-29 and M-30. ^[6] Among the 54 CTX-M group I ESBL producing Enterobacteriaceae, 31 isolates were Escherichia coli, 23 were Klebsiella species and none of the Proteus species produced CTX M ESBL's. Escherichia coli is the predominant CTX M group I ESBL producing Enterobacteriaceae in our study. Cefatoxime was considered to be the best 3GC antibiotic for phenotypic ESBL detection, as most of the isolates (75%) were positive in DDST for cefotaxime. CTX M beta lactamases has raised many concerns that, among the first 105 patients infected with CTX-M-15-producing Escherichia coli in Shropshire, there had been 28 deaths in 2002 as stated by D.M. Livermore P.M.Howkey, et al.^[1] The data of D.M.Livermore, Yuan M et al. is supportive of our study in which among the isolates with confirmed cephalosporin resistance, 51% were Escherichia coli, and a large number of Escherichia coli were with CTX-M enzymes. ^[14]

The same study shows that CTX M lactamases are increasingly prevalent in Enterobacteriaceae. ^[1] Endogenous intestinal flora formed by Enterobacteriaceae is the reservoir for CTX M beta lactamase infections and they colonize in the gut without harming the host. Munday CJ, et al., and Valverde A et al., have proved that CTX M ESBLs are carried by Enterobacteriaceae in the community fecal flora ^[15,16] and they are predominantly responsible for urinary tract infections. ^[20,21] This situation increases the potential of CTX M lactamases to disseminate rapidly in the community and produce serious infections which may not respond to the antibiotics that are used normally. D.M. Livermore, Yuan M, et al. has further mentioned that Enterobacteriaceae with CTX-M-15 (Group I) enzyme are resistant to inhibitor combinations (such as Piperacillin/Tazobactam and Amoxicillin/Clavulanate) by producing inhibitor-resistant penicillinases. ^[14] Reconsideration of antibiotics becomes mandatory and higher level antibiotics like Carbapenems may have to be used which in turn escalates the cost and duration of hospital stay for the patients.

This condition is even worse in Critical care units because of factors such as severity of illness in these patients, closeness with other patients, many invasive procedures (catheter, endotracheal tube, IV lines etc) and failure to follow aseptic conditions (hand washing etc). All these create a fertile environment for the antimicrobial resistant bacteria to disseminate in the Critical Care units which insists special care to be exercised in the management of Critical Care patients. Early detection of CTX M producing Enterobacteriaceae by repeated surveillance and usage of 3GC antibiotics under proper guidance could be the possible routes to prevent the emergence and spread of CTX M ESBL producing organisms.